Paltusotine
Paltusotine is the first somatostatin-type drug that works as a once-daily pill instead of a monthly injection. It was approved in 2025 for acromegaly and is being tested for the flushing and diarrhoea of carcinoid syndrome from small-bowel neuroendocrine tumours.
Overview
Paltusotine is Crinetics Pharmaceuticals' oral, non-peptide agonist of somatostatin receptor 2. In the phase 3 PATHFNDR trials in acromegaly it maintained IGF-1 control in patients switched from injected somatostatin analogues and achieved control in untreated patients, and the FDA approved it in September 2025 for the treatment of acromegaly in adults.
Carcinoid syndrome depends on the same receptor: the phase 3 CAREFNDR trial is testing paltusotine against placebo for flushing and bowel frequency in patients with carcinoid syndrome from neuroendocrine tumours. The small intestinal neuroendocrine tumour page names it, with a subcutaneous octreotide depot, among the symptom-control options in development after the injected analogues.
A small molecule that selectively activates somatostatin receptor 2, the receptor through which octreotide and lanreotide suppress growth hormone and the hormones that cause carcinoid syndrome, but taken as a once-daily tablet rather than an injection. Connects to Somatostatin receptor 2.
1.Paltusotine binds Somatostatin receptor 2.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2025 | Acromegaly in adults |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Paltusotine" OR ABSTRACT:"Paltusotine" OR TITLE:"Palsonify" OR ABSTRACT:"Palsonify" OR TITLE:"CRN00808" OR ABSTRACT:"CRN00808") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Paltusotine, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentPasireotide
Shares Somatostatin analogues (octreotide, lanreotide), Somatostatin receptor 2 and the tag subtype-drugs-wave.
- TreatmentPegvisomant
Shares Somatostatin analogues (octreotide, lanreotide) and the tag subtype-drugs-wave.
- TrialCarcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Shares Crinetics Pharmaceuticals, Small intestinal neuroendocrine tumours.
- IdeaSSTR antagonist radioligands to increase tumour dose
Shares Small intestinal neuroendocrine tumours, Somatostatin receptor 2.
- TrialPROMID
Shares Somatostatin analogues (octreotide, lanreotide), Small intestinal neuroendocrine tumours.
- TrialNETTER-1
Shares Somatostatin analogues (octreotide, lanreotide), Small intestinal neuroendocrine tumours, Somatostatin receptor 2.
- TermCarcinoid syndrome and carcinoid heart disease
Shares Somatostatin analogues (octreotide, lanreotide), Small intestinal neuroendocrine tumours.
- TermPRRT (peptide receptor radionuclide therapy)
Shares Somatostatin analogues (octreotide, lanreotide), Small intestinal neuroendocrine tumours, Somatostatin receptor 2.